New hope for bone cancer patients: access to unapproved immune therapy
NCT ID NCT04571229
Summary
This program provides access to an unapproved drug called L-MTP-PE for people with osteosarcoma (a type of bone cancer). The drug aims to help the body's own immune system fight and control the cancer after surgery. It is for patients whose doctors believe it could be beneficial and who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
AVAILABLENew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.